Losartan Global Market Report 2025

The losartan market size has grown steadily in recent years. It will grow from $1.44 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth during the historic period can be attributed to factors such as the increasing geriatric population, rising healthcare expenditure, a rise in diabetic nephropathy cases, greater awareness of blood pressure management, and the growing adoption of generic ARBs.

The losartan market size is expected to see steady growth in the next few years. It will grow to $1.79 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth during the forecast period can be attributed to factors such as the increasing demand for cost-effective antihypertensive drugs, a growing focus on preventive healthcare, the rising prevalence of lifestyle-related disorders, expanded healthcare access in emerging markets, and the continuous launch of generic formulations. Key trends during this period include advancements in drug delivery systems, the development of fixed-dose combination therapies, innovation in formulation technologies, improved manufacturing processes, and the development of personalized medicine approaches.

The growing prevalence of hypertension is expected to drive the expansion of the losartan market in the near future. Hypertension, characterized by persistently high blood pressure, increases the risk of heart disease, stroke, and other serious health issues. The rise in hypertension is often linked to diets rich in salt and processed foods, which cause fluid retention and increase the strain on the heart. Losartan helps manage hypertension by blocking angiotensin II, a hormone that narrows blood vessels. This action relaxes and widens the vessels, lowering blood pressure and reducing the heart's burden. For example, the American Heart Association reported that in January 2024, there were 131,454 deaths primarily associated with high blood pressure in 2022, an increase from 124,508 deaths in 2021. This rising prevalence of hypertension is driving the demand for losartan.

Major companies in the losartan market are focusing on creating innovative products to improve patient compliance and expand therapeutic uses. One such innovation is the losartan potassium oral suspension, a liquid form of losartan designed for people who find it difficult to swallow tablets. In March 2025, Scienture Holdings Inc., a US-based biopharmaceutical company, received FDA approval for Arbli, a ready-to-use liquid formulation for treating hypertension, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and managing diabetic nephropathy in type 2 diabetes patients. Arbli offers precise dosing without the need for compounding and comes in a 165 mL peppermint-flavored suspension (10 mg/mL), with an 18-month shelf life at room temperature.

In April 2025, Scienture Holdings, Inc. formed a partnership with Saptalis Pharmaceuticals to manufacture Arbli, a losartan potassium oral suspension (10 mg/mL). This collaboration includes warehousing and distribution agreements with strategic partners to ensure the successful market launch of the first FDA-approved ready-to-use oral liquid losartan, addressing the unmet needs in hypertension treatment. Saptalis Pharmaceuticals, based in the United States, is a key partner in this initiative.

Major players in the losartan market are Viatris Inc., Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Vasudha Pharma Chem Ltd., Unichem Laboratories Ltd., Global Pharma Tek, Manus Aktteva Biopharma LLP, Emcure Pharmaceuticals Ltd., Wellona Pharma, JPM Pharma & Chemicals Pvt. Ltd.

North America was the largest region in the losartan market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in losartan report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the losartan market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Losartan is an angiotensin II receptor blocker (ARB) commonly prescribed to treat high blood pressure and reduce the risk of stroke in patients with hypertension. It works by relaxing blood vessels, which makes it easier for the heart to pump blood. Losartan helps lower blood pressure, improves heart function, and protects kidney health, particularly in patients with diabetes.

The primary forms of losartan dosage include tablets, powder, and suspension. Losartan tablets are convenient, once-daily oral medications used to manage hypertension and diabetic nephropathy. It is sourced from various suppliers, including contract manufacturing organizations and in-house production, and is distributed through both online and offline channels. Losartan is used for a range of conditions, including hypertension, stroke, diabetic nephropathy, and more. It is suitable for use by a variety of end-users, including both adults and pediatrics.

The losartan market research report is one of a series of new reports that provides losartan market statistics, including the losartan industry global market size, regional shares, competitors with the losartan market share, detailed losartan market segments, market trends, and opportunities, and any further data you may need to thrive in the losartan industry. This losartan market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The losartan market consists of sales of losartan potassium tablets, losartan-hydrochlorothiazide combination tablets, and generic formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.